Subscribe to Drug Discovery & Development News

The Lead

Drug Firm AstraZeneca Reports Slide in Earnings

July 30, 2015 | by The Associated Press | Comments

Anglo-Swedish drug firm AstraZeneca said second-quarter net income fell 12 percent to $697 million as competition from generic drug companies reduced sales. Read more...

View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Scientists Receive $1.4M to Study Drug Candidates for Neurological Disorders, Other Diseases

July 31, 2015 9:51 am | by The Scripps Research Institute | Comments

The project involves studying what are known as RORs (retinoic acid receptor-related orphan receptors). Read more...


Amgen Hikes 2015 Forecast After 2Q Increase in Profit, Sales

July 31, 2015 9:39 am | by Linda A. Johnson, AP Business Writer | Comments

Amgen shares jumped in extended trading after the maker of osteoporosis drug Prolia easily beat Wall Street's second-quarter profit expectations and hiked its 2015 financial forecast. Read more...


Cipher Pharmaceuticals Announces Successful Completion of Second Phase 3 Study for Ozenoxacin

July 31, 2015 8:54 am | Comments

Company expects to submit Ozenoxacin for regulatory approval in Canada in the first quarter of 2016. Read more...


UN Ebola Mission Winds Down, WHO Takes Reins in West Africa

July 31, 2015 8:48 am | by Maria Cheng and Raphael Satter, Associated Press Medical Writer | Comments

The United Nations Mission for Ebola Emergency Response is officially winding down Friday. Read more...


Researchers Discover New Type of Mycovirus

July 31, 2015 8:40 am | by University of Hertfordshire | Comments

Virus infects the fungus Aspergillus fumigatus, which can cause the human disease aspergillosis. Read more...


'Cracking' Gluten Intolerance

July 31, 2015 8:39 am | by University of Alberta | Comments

Researchers may have found a way to help people with celiac disease enjoy the wide variety of foods they normally have to shun. Read more...


Health Care Spending to Accelerate, U.S. Report Says

July 30, 2015 1:25 pm | by Ricardo Alonso-Zaldivar, Associated Press | Comments

It's lasted six years. But now welcome relief from rising U.S. health care costs seems to be winding down. Read more...


Par Pharmaceutical Begins Shipment of Generic Megace ES

July 30, 2015 1:11 pm | Comments

Par’s launch of its authorized generic product follows a competitor’s introduction of the first generic version of Megace ES. Read more...


Roche Submits FDA Filing for Companion Diagnostic for NSCLC Drug Therapy

July 30, 2015 12:54 pm | Comments

Roche announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval (PMA) to the U.S. Food and Drug Administration. Read more...


Identifying a Key Growth Factor in Cell Proliferation

July 30, 2015 12:35 pm | by MIT | Comments

Mitochondria are well known for their role as powerhouses in our cells, using respiration to release the energy in the food we eat and trapping that energy in the molecule adenosine triphosphate, or ATP. Read more...


Mechanism Behind the Lack of Effectiveness of Certain Antagonist Drugs Discovered

July 29, 2015 11:05 am | by University of Barcelona | Comments

Researchers have published a study in the journal Proceedings of the National Academy of Sciences (PNAS) about the formation of G protein-coupled receptors (GPCRs) which allows understanding the unexpected behaviour of some antagonists that block physiological responses. Read more..


Mylan Gets European Clearance in Proposed Perrigo Takeover

July 29, 2015 11:00 am | Comments

Mylan NV said Wednesday that it received European regulatory approval to move forward with its proposed buyout of Perrigo Co., which has resisted repeated overtures. Read more...


Overcoming Why a New Treatment is Resisted by Lung Cancer

July 29, 2015 10:56 am | by University of Manchester | Comments

A promising agent for the treatment of cancer has so far had little effect on the most common lung tumours, but new research from The University of Manchester has suggested how this resistance might be overcome. Read more...


Sanofi Announces that First LixiLan Phase 3 Study Met Primary Endpoint

July 29, 2015 10:50 am | Comments

Sanofi announced yesterday that the LixiLan-O Phase 3 clinical trial met its primary objective in patients with type 2 diabetes treated with metformin. The fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide, a GLP-1 RA, demonstrated statistically superior reduction in HbA1c (average blood glucose over the previous three months) compared with lixisenatide and compared with insulin glargine 100 units/mL. Read more...


Indivior: FDA Acceptance of Naloxone Nasal Spray NDA With Priority Review

July 29, 2015 10:39 am | Comments

Indivior PLC today announced that the New Drug Application (NDA) for naloxone nasal spray was accepted and received Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of opioid overdose.  Read more..



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.